

# Journal Pre-proof

Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery

Emanuele Chisari, MD, Chad A. Krueger, MD, C. Lowry Barnes, MD, Stefaan Van Omsen, MD, William Walter, MD, Javad Parvizi, MD FRCS



PII: S0883-5403(20)30436-8

DOI: <https://doi.org/10.1016/j.arth.2020.04.049>

Reference: YARTH 57969

To appear in: *The Journal of Arthroplasty*

Received Date: 16 April 2020

Revised Date: 16 April 2020

Accepted Date: 17 April 2020

Please cite this article as: Chisari E, Krueger CA, Lowry Barnes C, Van Omsen S, Walter W, Parvizi J, Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery, *The Journal of Arthroplasty* (2020), doi: <https://doi.org/10.1016/j.arth.2020.04.049>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc.

**Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery.**

Emanuele Chisari MD<sup>1</sup>, Chad A. Krueger MD<sup>1</sup>, C. Lowry Barnes MD<sup>2</sup>, Stefaan Van Omsen MD<sup>3</sup>,  
William Walter MD<sup>3</sup> Javad Parvizi MD FRCS<sup>1\*</sup>

<sup>1</sup>Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, US

<sup>2</sup>Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, US

<sup>3</sup>Royal North Shore Hospital, Sydney, Australia

\*Correspondence should be addressed to:

Javad Parvizi MD

125 S 9<sup>th</sup> Street, Suite 1000, Philadelphia, PA, US

1 **Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery**

2 Emanuele Chisari MD<sup>1</sup>, Chad A, Krueger MD<sup>1</sup>, C. Lowry Barnes MD<sup>2</sup>, Stefaan Van Omsen MD <sup>3</sup>,

3 William Walter MD <sup>3</sup> Javad Parvizi MD FRCS<sup>1\*</sup>

4

5 <sup>1</sup>Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, US

6 <sup>2</sup> Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, US

7 <sup>3</sup>Royal North Shore Hospital, Sydney, Australia.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23 \*Correspondence should be addressed to:

24 Javad Parvizi MD

25 125 S 9<sup>th</sup> Street, Suite 1000, Philadelphia, PA, US

26

## 27 **Introduction**

28 The date was September 28<sup>th</sup>, 1918. 200,000 Philadelphia and Pennsylvania citizens united to celebrate  
29 the end of World War I. It was the day of the Liberty Loan Parade, a government initiative to promote the  
30 new bonds being issued to pay for war-associated cost. Most of the city's population joyfully attended the  
31 event. Three days later, 635 of attendees of the event fell ill to what was assumed to be common flu. By  
32 six months, over 16,000 of the event participants had died, and a half million more were infected in  
33 Pennsylvania. [1–3] Such was the power and impact of the 'Spanish Flu' (H1N1) which remains one of  
34 the worst pandemics in our history. Based on some estimations, it killed over 50 million people around  
35 the globe [1]. Ironically, and within the context of current pandemic 102 years later, some lessons are  
36 being re-learnt.

37  
38 While the outbreak of COVID-19, caused by SARS-CoV-2, does not appear to be on the same scale as  
39 the pandemic of 1918, it does share some of the same signatures of the "Spanish-flu" and, for that matter,  
40 some more recent pandemics. All of these pandemics were caused by a virus originating from an animal  
41 source and spreading amongst humans by droplets and/or contact with bodily fluids. [4]. The SARS-Cov-  
42 1 epidemic during 2002-2004, which started in China, was also caused by a coronavirus and killed 774  
43 people with a 9% fatality rate [5]. In 2009, the H1N1 pandemic spread across the globe and killed over  
44 18,000 people in the United States alone [6,7]. Then, in 2012, another fatal coronavirus, known as Middle  
45 East Respiratory Syndrome (MERS), hit the Arabic peninsula[8]. All of these outbreaks were similar to  
46 what we face today but occurred on a much smaller scale. The major difference between the current  
47 pandemic, caused by SARS-CoV-2, and those before it is that the current virus appears to be highly  
48 contagious. In fact, COVID-19 has already caused ten-times as many cases as SARS in a quarter of the  
49 time [9]. The SARS-CoV-2 virus can also infect some people without causing many, or any, symptoms  
50 and is capable of surviving on surfaces for a relatively long period of time. The aforementioned qualities  
51 of SARS-CoV-2 makes the current COVID-19 pandemic a truly challenging one to manage. Especially

52 when considering that we live in an increasingly connected world that appears ideally suited for the rapid  
53 spread of diseases across countries and continents.

54

55 The medical community has been mindful of infection origination and pathogen transfer for  
56 centuries. As surgeons, we meticulously exercise the necessary steps to decrease the possibility of  
57 pathogen transfer and are acutely aware of the consequences of infection affecting our patients. Societies  
58 also have considerable knowledge regarding the importance of “breaking the chain of pathogen transfer”.  
59 In the middle of 19<sup>th</sup> century, Ignac Semmelweis, known as the Saviour of Mothers, [10] recognized the  
60 personal chain of pathogen transfer and mandated hand-washing to disrupt this process. Quarantines have  
61 an even more remote history, dating back to 14<sup>th</sup> century[11]. In an effort to protect the coastal cities from  
62 diseases arriving on incoming boats, passengers were placed in isolation for a period of time and  
63 monitored for the presence of disease before being allowed to interact with the local community. All of  
64 the measures implemented to address the COVID-19 pandemic, which have been in practice in the  
65 medical and surgical community for centuries, are intended to break the chain of pathogen transfer. There  
66 is no doubt that this pandemic shall also pass and we will return to our “normal” lives. Many, however,  
67 believe that the new normalcy will have different features than what was present prior to COVID-19. Our  
68 profession will also witness changes in everyday routines that will be necessary to overcome the issues  
69 with the current pandemic and diminish the scale and gravity of future epidemic/pandemics. As we  
70 prepare to emerge from this pandemic and contemplate resuming our practices, we are faced with the  
71 ever-pertinent question of what changes will we need to implement in our daily routines. This article is  
72 written, with reliance on available evidence from the past and the current events, to provide some  
73 guidance on strategies that may need to be implemented to disrupt the chain of pathogen transfer. These  
74 strategies may also translate to a reduction in the rate of surgical site infections in the future.

75

76 **Resuming Elective Arthroplasty**

77 There will come a day, hopefully in not so distant of a future, when the current pandemic subsides and  
78 elective surgical procedures are resumed. The decision of when to re-start elective procedures will be a  
79 complicated one being affected by societal, political, geographic, economic and health related factors.  
80 Once such normalcy resumes, we have to entertain the major question of what changes we will need to  
81 introduce in our practices to prevent the spread of SARS-CoV-2 from infected hosts to others. We will  
82 also need to be cognizant of the potential for re-infection with the virus and the emergence of a second  
83 wave.

84 While any discussion regarding a SARS-CoV-2 ‘reinfection’ remains theoretical, a few recent  
85 articles have raised this possibility [12,13]. If such a phenomenon is indeed possible, three distinct  
86 explanations exist. First, patients who contract the disease do not develop lasting immunity against the  
87 virus and are just as vulnerable as those without a prior infection in contracting the disease. Second, there  
88 are issues with the accuracy of the test, with false positives and false negatives existing. So, it is possible  
89 that some of these presumed reinfections are a result of the re-test being a false negative result which was  
90 incorrectly interpreted as **the** individual being declared as “cured”. Finally, it is plausible, and indeed  
91 scientifically proven [14–17], that viruses undergo marked genetic mutations, even during an active  
92 pandemic. Hence those infected with the virus develop partial immunity and are still vulnerable for  
93 infection with the ‘new’ mutated version of the virus [14–17]. We are familiar with the concept of partial  
94 immunity as it relates to the flu-vaccine, as it affords only 60-70% immunity against the disease in any  
95 given year [18]. Based on scientific data, the genetic footprint of the initial SARS-CoV-2 affecting  
96 individuals in Wuhan is different than the RNA sequence of the virus affecting people in other countries  
97 [19]. The virus has certainly undergone mutation. In fact, these mutations likely explain why some  
98 epidemics come to an abrupt end as the continued viral alterations may revoke the virulence of the  
99 pathogen.

100 So, without an effective vaccine against the virus, and without an absolute test for detection of the  
101 disease, we need to assume that every patient under our care, and for that matter healthcare personnel  
102 around us in the hospitals, are potential carriers of the virus and capable of spreading the infection. The

103 latter does not imply that we should not insist on large scale testing of every individual who comes out of  
104 social isolation and enters the society. The medical profession is aware of the importance of “screening”  
105 patients for a condition or a disease. Identifying carriers of a pathogen is critical step in disruption of the  
106 chain of transfer.

107

### 108 **Disrupting the chain of pathogen transfer**

109 Infection, either viral, bacterial or fungal, can be transferred from one individual to another through air  
110 (droplets), direct contact with skin or bodily fluids or contact with a surface harboring the pathogens.  
111 Here, we summarize the importance of good practices that are known to be effective in disrupting the  
112 chain of pathogen transfer. We are aware that there remains many unknowns regarding COVID-19 and  
113 excited that the scientific discoveries and innovations arising from the current pandemic will serve the  
114 society in general, and healthcare profession in particular, for years to come.

115

#### 116 *Patient screening.*

117

118 To determine the risk of a patient being infected with SARS-COV-2, all patients scheduled for elective  
119 surgery should be screened for symptoms and exposure. Symptoms of infection include fever, sore  
120 throat, cough, and anosmia are common with a COVID-19 infection. Patients should also be asked if they  
121 have been exposed to anyone with known COVID-19 infection or anyone with symptoms of COVID-19  
122 to determine the risk. Furthermore, the rate of infection in the community will be important as well as a  
123 patient’s history of travel from a region with known high rates of COVID-19 infection.

124

125 Routine screening of nasopharyngeal swabs or throat swabs by PCR (polymerase chain reaction) to detect  
126 viral genetic material is subject to false positive and false negative results, and is therefore not indicated  
127 in low-risk patients. Serological tests for IgG and IgM are not currently widely available but may become  
128 useful tools to determine the patient’s status. There is limited data on their accuracy and they are not

129 regulated in the same manner as more standard antibody tests at this time so enthusiasm for these tests  
130 need to be tempered. All of these tests will undergo further refinements as we continue to expand our  
131 knowledge regarding immunity to COVID-19. We believe that questions regarding who should be  
132 screened and what screening should be in place is a pertinent one. Most, if not all, institutions will need to  
133 have access to a rapid turnaround test for COVID-19. A point of care test is currently available and  
134 should be utilized for emergency cases. Industry has also been able to develop special swabs that can be  
135 used to detect the presence of SARS-CoV-2 in the oral cavity, eliminating the need for more invasive  
136 nasopharyngeal swabs for testing.

137

#### 138 *Prevention of transfer through direct contact*

139

140 Direct contact with an infected host is also a major pathway for the spread of pathogens. Thus, wearing  
141 protective gloves and gowns by all in the OR should be routine. Furthermore, scrub changes should be  
142 frequent throughout the day. Again, without a widespread screening mechanism in place for COVID-19,  
143 it is impossible for us to determine who is 'safe.' Another mechanism to glean information about the  
144 status of a patient would be the use of an antibody testing to identify those who had contracted the disease  
145 and developed immunity.

146

#### 147 *Prevention of spread in the air*

148

149 Aerosolized particles have proven to be a mechanism of spread of SARS-CoV-2[20]. Aerosolization of  
150 virus particles usually does not occur with breathing or talking but some procedures in the operating room  
151 may cause aerosolization of virus particles. Droplets are expelled during talking and breathing but these  
152 usually do not become aerosolized and land on surfaces within a few minutes. Patients undergoing  
153 elective arthroplasty should be supplied with a simple surgical mask that will prevent the spread of  
154 droplets carrying the virus. Personal protection equipment (PPE) should be available to all the healthcare



155 workers and should focus on masks that are able to filter any pathogen, while allowing for enough  
156 comfort to be worn for a substantial length of time. We, as surgeons, and healthcare workers in general,  
157 should also be fitted with such masks.

158 It is fortunate that the majority of arthroplasties are performed under regional anesthesia.  
159 Intubation of patient can cause aerosolization of a large number of particles in the upper airways and  
160 particular caution should be taken with this procedure when there is a risk that the patient may be carrying  
161 SARS-COV-2. Anesthesia teams dealing with patients who require general anesthesia and airway  
162 management should be fitted with secure personal protection equipment (PPE). As orthopaedic surgeons,  
163 we use power tools (drills, saws, etc.) that releases aerosolized material [21] containing blood, bone and  
164 fat tissue. The amount of virus particles in these tissues is not known but these instruments could  
165 potentially aerosolize virus particles in the operating room. In patients who are positive for the virus,  
166 when surgery cannot be delayed, the power settings should be as low as possible, and suction devices  
167 should be carefully handled to remove any aerosol formation [22]. This may include suction fitted to  
168 electrocautery devices or sterile towels dropped over cutting surfaces to potentially decrease the amount  
169 of aerosolized.

170 In cases of known SARS-CoV-2 positive patients, surgeons and other healthcare workers should also  
171 have ventilation systems that are able to filter and capture SARS-CoV-2, as well as other bacteria and  
172 fungi. These systems can be used outside of the operating area but should be present in every operating  
173 room. Given that coronaviruses are approximately 0.125  $\mu\text{m}$  (125  $\mu\text{m}$ ) in diameter [23] high-efficiency  
174 particulate air (HEPA) filters might be one possible solution. [24] Thus, filtration of the operating room  
175 with devices that intake the air and remove the micro-organisms may be preferable to the positive  
176 pressure laminar flow settings. Negative pressure operating rooms will reduce the risk of virus particles  
177 being forced out of the room into the corridors.

178 The current surgical helmets (by Stryker and Zimmer-Biomet, for example) are not protective against  
179 spread of virus, as learnt during the 2012 SARS epidemic. They are designed to protect the user against  
180 splash back and can actually pull and condense sub-micron particles within the hood system [25]. All

181 reusable material should also be sanitized or sterilized at the conclusion of each procedure. Tests on the  
182 proper length of use for each mask and eventual reusing, should be performed to provide evidence-based  
183 guidelines to medical staff. Many questions remains: How long we should wear the mask?; How often  
184 should we change the masks?; Can the masks be sterilized and safely reused? And many others still  
185 remain unanswered. Further data is needed in order to provide evidence-based recommendations on these  
186 issues.

187

188

### 189 *Decontamination of Surfaces*

190

191 Every pathogen is capable of surviving on inanimate surfaces for a period of time [26]. We have come to  
192 understand that SARS-CoV-2 is a robust virus capable of surviving on the surfaces of metal and plastic  
193 for up to a few days and is not easily removed by standard air filtration systems [20,27,28]. Thus, another  
194 approach to disrupt the chain of pathogen transfer needs to concentrate on the decontamination and  
195 sanitization of inanimate and skin surfaces. One agent that has been demonstrated to be viricidal,  
196 including activity against coronaviruses, is dilute povidone iodine [29–31]. Dilute povidone iodine was  
197 tested against SARS, MERS and Ebola and found to have absolute efficacy. Other agents with potential  
198 activity against viruses, as well as bacterial and fungal pathogens, includes hypochlorite and high-  
199 concentration alcohol. Thus, it is crucial that all reusable material in the OR, that includes helmets, lead  
200 aprons, tourniquets, X-ray machines, navigation consoles, keyboards, screens and robots be sanitized and  
201 decontaminated routinely. The current sterilization systems in the hospitals for instruments and trays are  
202 effective in eliminating viruses and may not need to be altered. We may, however, need to implement a  
203 practice that requires these instruments to be placed in a bath of antiseptic solution during the procedure  
204 to prevent potential contamination. We must also be aware that there is a wide variation in the terminal  
205 cleaning of the operating rooms across the globe. Effective infection prevention and viricidal protocols  
206 need to be implemented in every operating room and arguably in every patient room after discharge.

207

208 Conclusion

209 The current pandemic has taken us into uncharted territories. The economic and health impact of this  
210 pandemic may be irreversible and will be felt for years to come. While we mourn the loss of lives to this  
211 pandemic, society needs to prepare for the eventual lift of social isolation and attempt to return to  
212 normalcy. As our knowledge of this pathogen expands and we continue to work towards an effective  
213 vaccine and potential treatments for SARS-CoV-2, further strategies for the disruption of the chain of  
214 pathogen transfer needs to implemented. We have attempted to highlight some of the changes that  
215 orthoplasty surgeons will need to instigate now and when elective arthroplasties are resumed (**table 1**).  
216 While SARS-CoV-2 may be a novel pathogen, the actions needed to protect ourselves and our patients  
217 against the pathogen are not. The medical community and, more specifically, orthopedic surgeons have  
218 been acutely aware of the devastating impact of infections for centuries. We, as a medical community,  
219 have always been in the forefront of developing infection prevention protocols and implementing  
220 evidence-based strategies to combat these pathogens. Our fight against the COVID-19 will be no  
221 different. The ultimate changes that we implement as a result of this pandemic stand to serve our patients  
222 and the society well for years to come and help us all safely return to caring for our patients.

223

224 **References**

- 225 [1] Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish”  
226 influenza pandemic. *Bull Hist Med* 2002;76:105–15. doi:10.1353/bhm.2002.0022.
- 227 [2] 1918 Pandemic (H1N1 virus) | Pandemic Influenza (Flu) | CDC n.d.  
228 <https://www.cdc.gov/flu/pandemic-resources/1918-pandemic-h1n1.html> (accessed April 10,  
229 2020).
- 230 [3] Starr I. Influenza in 1918: Recollections of the epidemic in Philadelphia. *Ann Intern Med*  
231 2006;145:138–40. doi:10.7326/0003-4819-145-2-200607180-00132.
- 232 [4] Gates B. The next epidemic - Lessons from Ebola. *N Engl J Med* 2015;372:1381–4.  
233 doi:10.1056/NEJMp1502918.
- 234 [5] World Health Organization. WHO | Summary of probable SARS cases with onset of illness from 1  
235 November 2002 to 31 July 2003 2015.
- 236 [6] Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel  
237 swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 2009;360:2605–15.  
238 doi:10.1056/NEJMoa0903810.
- 239 [7] Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects  
240 of pandemic 2009 influenza a (H1N1) virus infection. *N Engl J Med* 2010;362:1708.  
241 doi:10.1056/NEJMra1000449.
- 242 [8] About Middle East Respiratory Syndrome (MERS) | CDC n.d.  
243 <https://www.cdc.gov/coronavirus/mers/about/index.html> (accessed April 10, 2020).
- 244 [9] Gates B. Responding to Covid-19 — A Once-in-a-Century Pandemic? *N Engl J Med* 2020.  
245 doi:10.1056/nejmp2003762.
- 246 [10] Dunn PM. Ignac Semmelweis (1818-1865) of Budapest and the prevention of puerperal fever.  
247 *Arch Dis Child Fetal Neonatal Ed* 2005;90:F345. doi:10.1136/adc.2004.062901.
- 248 [11] Gensini GF, Yacoub MH, Conti AA. The concept of quarantine in history: From plague to SARS.  
249 *J Infect* 2004;49:257–61. doi:10.1016/j.jinf.2004.03.002.

- 250 [12] Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in  
251 COVID-19: A case report. *Int J Infect Dis* 2020;93:297–9. doi:10.1016/j.ijid.2020.03.003.
- 252 [13] Zhang J, Yan K, Ye H, Lin J, Zheng J, Cai T. SARS-CoV-2 turned positive in a discharged patient  
253 with COVID-19 arouses concern regarding the present standard for discharge. *Int J Infect Dis*  
254 2020;0. doi:10.1016/j.ijid.2020.03.007.
- 255 [14] Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new  
256 coronavirus epidemic: Evidence for virus evolution. *J Med Virol* 2020;92:455–9.  
257 doi:10.1002/jmv.25688.
- 258 [15] Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in  
259 the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI J* 2020;19:410–7.  
260 doi:10.17179/excli2020-1167.
- 261 [16] Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, et al. The establishment of reference sequence for  
262 SARS-CoV-2 and variation analysis. *J Med Virol* 2020. doi:10.1002/jmv.25762.
- 263 [17] Stefanelli P, Faggioni G, Lo Presti A, Fiore S, Marchi A, Benedetti E, et al. Whole genome and  
264 phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020:  
265 additional clues on multiple introductions and further circulation in Europe. *Eurosurveillance*  
266 2020;25. doi:10.2807/1560-7917.es.2020.25.13.2000305.
- 267 [18] Zhang X, Zhao Y, Neumann AU. Partial immunity and vaccination for influenza. *J Comput Biol*  
268 2010;17:1689–96. doi:10.1089/cmb.2009.0003.
- 269 [19] Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2  
270 genomes. *Proc Natl Acad Sci* 2020:202004999. doi:10.1073/pnas.2004999117.
- 271 [20] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al.  
272 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*  
273 2020. doi:10.1056/nejmc2004973.
- 274 [21] Yeh HC, Jones RK, Muggenburg BA, Turner RS, Lundgren DL, Smith JP. Characterization of  
275 aerosols produced during surgical procedures in hospitals. *Aerosol Sci Technol* 1995;22:151–61.

- 276 doi:10.1080/02786829408959736.
- 277 [22] Zheng MH, Boni L, Facs MD, Fingerhut A. Minimally invasive surgery and the novel coronavirus  
278 outbreak: lessons learned in China and Italy. n.d.
- 279 [23] Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis.  
280 Coronaviruses Methods Protoc., Springer New York; 2015, p. 1–23. doi:10.1007/978-1-4939-  
281 2438-7\_1.
- 282 [24] Martsolf GR, Barrett ML, Weiss AJ, Kandrack R, Washington R, Steiner CA, et al. Impact of  
283 race/ethnicity and socioeconomic status on risk-adjusted hospital readmission rates following hip  
284 and knee arthroplasty. *J Bone Jt Surg - Am Vol* 2016;98:1385–91. doi:10.2106/JBJS.15.00884.
- 285 [25] Derrick JL, Gomersall CD. Surgical Helmets and SARS Infection. *Emerg Infect Dis* 2004;10:277–  
286 9. doi:10.3201/eid1002.030764.
- 287 [26] Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate  
288 surfaces? A systematic review. *BMC Infect Dis* 2006;6:130. doi:10.1186/1471-2334-6-130.
- 289 [27] Tsai Y-H, Wan G-H, Wu Y-K, Tsao K-C. Airborne Severe Acute Respiratory Syndrome  
290 Coronavirus Concentrations in a Negative-Pressure Isolation Room. *Infect Control Hosp*  
291 *Epidemiol* 2006;27:523–5. doi:10.1086/504357.
- 292 [28] Booth TF, Kournikakis B, Bastien N, Ho J, Kobasa D, Stadnyk L, et al. Detection of Airborne  
293 Severe Acute Respiratory Syndrome (SARS) Coronavirus and Environmental Contamination in  
294 SARS Outbreak Units. *J Infect Dis* 2005;191:1472–7. doi:10.1086/429634.
- 295 [29] Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub  
296 products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified  
297 vaccinia virus Ankara, the new European test virus for enveloped viruses. *BMC Infect Dis*  
298 2015;15:375. doi:10.1186/s12879-015-1111-9.
- 299 [30] Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine,  
300 physical conditions and chemical reagents. *Dermatology*, vol. 212, 2006, p. 119–23.  
301 doi:10.1159/000089211.

- 302 [31] Eggers M, Eickmann M, Zorn J. Rapid and Effective Virucidal Activity of Povidone-Iodine  
303 Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified  
304 Vaccinia Virus Ankara (MVA). *Infect Dis Ther* 2015;4:491–501. doi:10.1007/s40121-015-0091-9.  
305  
306

Journal Pre-proof

<b>SURGICAL STEP</b>	<b>SUGGESTED ACTION</b>
<b>WAITING ROOM</b>	These should not be used. Family members can be called when the surgery is complete and should not enter or wait within the hospital unnecessarily.
<b>CHECK-IN</b>	A form of 'mobile' check-in would be preferable where the patient can call the desk and, when the staff is ready, be escorted directly to their pre-operative holding area room and provided a mask. Patients would ideally not stop at a 'front desk.'
<b>PRE-OPERATIVE HOLDING AREA</b>	Registration would ideally take place here before each patient prepared for surgery. All beds should be adequately spaced. If curtains separate beds, they should be cleaned after each patient.
<b>OPERATING ROOMS</b>	Each operating room would ideally have its own air-handling system to minimize air-based contamination and consider using high-efficiency particulate air (HEPA) filters. Minimize the number of people in the room. Minimize non-sterile equipment such as X-ray machines, navigation consoles and robots as virus may last up to 72 hours on these surfaces.
<b>ANESTHESIA</b>	Spinal anesthesia should be used preferentially over general anesthesia to decrease aerosolized particles from each patient within the operating room.
<b>SURGICAL HOODS/HELMETS</b>	Surgical helmets/hoods should be modified for increased protection against viruses for those wearing these systems. Alternatively, operating room personnel can eschew the helmets/hoods and use a N-95 mask and face shield in their place.
<b>FORCED-AIR WARMING SYSTEM</b>	These devices should be used with caution as they may increase the distribution of aerosolized particles during the case. Blankets may be more effective at decreasing particulate generation and distribution.
<b>SCRUBS ROOM TURNOVER</b>	Scrubs should be changed frequently, potentially after each patient. Each room should be cleaned between cases with solutions such as dilute povidone-iodine and alcohol that are effective against viruses and other pathogens.
<b>POST-ANESTHESIA CARE UNIT</b>	All beds should be adequately spaced. If curtains separate beds, they should be cleaned after each patient. Patients who are not going home on the same day should be brought to their hospital room expeditiously.
<b>HOSPITAL STAY</b>	If patients can be safely discharged on the same day as their surgery, they should be sent home. Protocols should be in place to facilitate this process and patients and their families should be educated of this policy prior to undergoing their total joint arthroplasty.
<b>'ROUNDS'</b>	Telemedicine should be used to 'round' on the patients post-operatively to limit direct contact.

**Table 1:** Common steps for the surgical procedure and recommendations for decreasing the potential viral load for each step.